The review considers commercial insulin formulations. Speсial attention is paid to the difficulties and strategies of development of alternative hormone delivery systems (buccal, transdermal, intranasal, pulmonary and oral). At the moment there is only one approved formulation of the noninvasive insulin in the world.
Raz I., Dubinsky A., Kidron M., Wainstein J. (2005) American Diabetes Association, 65th Annual Meeting & Scientific Sessions, San Diego, USA. http://www.generex.com/abstracts/ADA_Type2_Orallyn.pdf . Scholar google search